In vitro and in vivo activity of aurintricarboxylic acid preparations against Cryptosporidium parvum

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 5, 2008, Pages 1101-1104

  Klein, Pavel ^a   Cirioni, Oscar ^b   Giacometti, Andrea ^b   Scalise, Giorgio ^b  

^a INSTITUTE OF ANIMAL SCIENCE   (Czech Republic)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Cell culture; Chemotherapy; Experimental infection; Flow cytometry; Neonatal mice

Indexed keywords

AURINTRICARBOXYLIC ACID; PAROMOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; C57BL 6 MOUSE; CELL CULTURE; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; OOCYST; SPOROZOITE;

ANIMALS; ANTIPROTOZOAL AGENTS; AURINTRICARBOXYLIC ACID; CELL COUNT; CELL SURVIVAL; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; FEMALE; MICE; MICE, INBRED C57BL;

EID: 54549123674     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn303     Document Type: Article

References (18)

1. O'Donoughe PJ. Cryptosporidium and cryptosporidiosis in man and animals. Int J Parasitol 1995; 25: 139-95.
2. de Graaf DC, Vanopdenbosch E, Ortega-Mora LM et al. A review of the importance of cryptosporidiosis in farm animals. Int J Parasitol 1999; 29: 1269-87.
3. Jenkins MC. Present and future control of cryptosporidiosis in humans and animals. Expert Rev Vaccines 2004; 3: 669-71.
4. Giacometti A, Burzacchini F, Cirioni O et al. Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis. Eur J Clin Microbiol Infect Dis 1999; 18: 885-9.
5. Klein P. Preventive and therapeutic efficacy of halofuginonelactate against Cryptosporidium parvum in spontaneously infected calves: A centralised, randomised, double-blind, placebo-controlled study. Vet J 2008; 177: 429-31.
6. Balzarini J, Mitsuya H, De Clercq E et al. Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. Biochem Biophys Res Commun 1986; 136: 64-71.
7. Hallick RB, Chelm BK, Gray PW et al. Use of aurintricarboxylic acid as an inhibitor of nucleases during nucleic acid isolation. Nucleic Acids Res 1977; 4: 3055-64.
8. González RG, Blackburn BJ, Schleich T. Fractionation and structural elucidation of the active components of aurintricarboxylic acid, a potent inhibitor of protein nucleic acid interactions. Biochim Biophys Acta 1979; 562: 534-45.
9. Gagliardi AR, Collins DC. Inhibition of angiogenesis by aurintricarboxylic acid. Anticancer Res 1994; 14: 475-9.
10. Owens MR, Holme S. Aurin tricarboxylic acid inhibits adhesion of platelets to subendothelium. Thromb Res 1996; 81: 177-85.
11. Liang F, Huang Z, Lee SY et al. Aurintricarboxylic acid blocks in vitro and in vivo activity of YopH, an essential virulent factor of Yersinia pestis, the agent of plague. J Biol Chem 2003; 278: 41734-41.
12. He R, Adonov A, Traykova-Adonova M et al. Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid. Biochem Biophys Res Commun 2004; 320: 1199-203.
13. Giacometti A, Cirioni O, Del Prete MS et al. In vitro effect on Cryptosporidium parvum of short-term exposure to cathelicidin peptides. J Antimicrob Chemother 2003; 51: 843-7.
14. Arrowood MJ, Sterling CR. Isolation of Cryptosporidium oocysts and sporozoites using discontinuous sucrose and isopycnic Percoll gradients. J Parasitol 1987; 73: 314-9.
15. Tzipori S. Cryptosporidiosis: Laboratory investigations and chemotherapy. Adv Parasitol 1998; 40: 187-221.
16. Casemore DP, Armstrong M, Sands RL. Laboratory diagnosis of cryptosporidiosis. J Clin Pathol 1985; 38: 1337-41.
17. Cushman M, Kanamathareddy S, De Clercq E et al. Synthesis and anti-HIV activities of low molecular weight aurintricarboxylic acid fragments and related compounds. J Med Chem 1991; 34: 337-42.
18. Tsutsui K, Seki S, Tsutsui K et al. Fractionation of aurintricarboxylic acid and effects of its components on nuclear swelling and nucleic acid synthesis. Biochim Biophys Acta 1978; 517: 14-23.